A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Public ClinicalTrials.gov record NCT07546500. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Study identification
- NCT ID
- NCT07546500
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Industry
- Enrollment
- 420 participants
Conditions and interventions
Conditions
Interventions
- Azenosertib Drug
- Investigator's choice of Chemotherapy Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 16, 2026
- Primary completion
- May 30, 2028
- Completion
- Apr 29, 2030
- Last update posted
- May 18, 2026
2026 – 2030
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 0107 | Phoenix | Arizona | 85016 | Not yet recruiting |
| Site 0110 | Antioch | California | 94531 | Not yet recruiting |
| Site 0115 | San Francisco | California | 94109 | Not yet recruiting |
| Site 0101 | Torrance | California | 90505 | Recruiting |
| Site 0111 | Camden | New Jersey | 08103 | Not yet recruiting |
| Site 0108 | Columbus | Ohio | 43026 | Not yet recruiting |
| Site 0105 | Portland | Oregon | 97210 | Not yet recruiting |
| Site 0109 | Philadelphia | Pennsylvania | 19104 | Not yet recruiting |
| Site 0113 | Philadelphia | Pennsylvania | 19111 | Not yet recruiting |
| Site 0114 | Willow Grove | Pennsylvania | 19090 | Not yet recruiting |
| Site 0112 | Sioux Falls | South Dakota | 57105 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07546500, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07546500 live on ClinicalTrials.gov.